The effect of zoledronic acid on serum osteoprotegerin in early stage multiple myeloma

Haematologica

Volumn 91, Issue 12, 2006, Pages 1720-1721

  Martini, Giuseppe ^a,b   Gozzetti, Alessandro ^a   Gennari, Luigi ^a   Avanzati, Annalisa ^a   Nuti, Ranuccio ^a   Lauria, Francesco ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Multiple myeloma; Osteoprotegerin; RANKL; Zoledronic acid

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; ZOLEDRONIC ACID;

ARTICLE; BLOOD LEVEL; DENSITOMETRY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMATOPOIETIC STEM CELL; HUMAN; MULTIPLE MYELOMA; OSTEOBLAST; OSTEOCLAST;

DIPHOSPHONATES; HUMANS; IMIDAZOLES; MULTIPLE MYELOMA; OSTEOPROTEGERIN;

EID: 33845923381     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Roodman GD. Biology of osteoclast activation in cancer. J Clin Oncol 2001;19:2892-8.
2. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
3. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-23.
4. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001;98:3527-33.
5. Viereck V, Emons G, Lauck KH, Frosch KH, Blaschke S, Grundker C, et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primaryhuman osteoblasts. Biochem Biophys Res Commun 2002;291:680-6.
6. Martini G, Gennari L, Merlotti D, Salvadori S, Franci MB, Campagna S, et al. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone. Bone[Epub ahead of print].
7. Musto P, Falcone A, Sanpaolo G, Bodenizza C, Carella AM. Pamidronate in early-stage untreated myeloma. J Clin Oncol 2003;16:3177-8.
8. Terpos E, Politou M, Rahemtulla A. The role of markers of bone remodelling in multiple myeloma. Blood Rev 2005;19:125-42.
9. Musto P, Falcone A, Sanpaolo G, Bodenizza C, Cascavilla N, Melillo L, et al. Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial. Leuk Lymphoma 2003;44:1545-8.